FDA pauses milk quality testing amid Health and Human Services cuts; lab transfer planned
FDA pauses milk quality testing amid Health and Human Services cuts; lab transfer planned
The U.S. Food and Drug Administration has suspended its quality control program that tests milk and other dairy products.
The Food Emergency Response Network Proficiency Testing Program is currently in the process of transferring to another lab that will allow the program to continue, an FDA spokesperson confirmed in a statement to USA TODAY on April 22.
"In the meantime, state and federal labs continue to analyze food samples, and FDA remains committed to working with states to protect the safety of the pasteurized milk supply," the agency said.
An internal email sent by the agency's Division of Dairy Safety said the proficiency testing program for Grade "A" raw milk and finished products is suspended effective since April 21, according to Reuters.
Pause comes after health department layoffs
The disruption comes after the Department of Health and Human Services cut 10,000 jobs across agencies earlier in April, including the FDA, as well as sister agencies like the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.
However, the FDA spokesperson did not confirm that staffing had any correlation with the pause of the quality control program.
Among those laid off were FDA staffers who played a role in the federal response to the ongoing bird flu outbreaks, according to former staff and professional groups.
When asked about cuts to FDA this month, a Department of Health and Human Services spokesperson referred to public statements and a fact sheet from the agency and HHS Secretary Robert F. Kennedy Jr.
Contributing: Eduardo Cuevas
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Kennedy names 8 vaccine committee replacements, including COVID shot critic
NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
27 minutes ago
- Yahoo
RFK Jr. Bombarded Bill Nye With Endless Anti-Vax Text Screeds
Robert F. Kennedy Jr. sent a flood of texts to Bill Nye trying to convince the beloved 'Science Guy' of his anti-vax claims. The old text chain, sent before Kennedy became Donald Trump's health secretary, was revealed by Nye during a Men's Health profile of the children's television presenter. The barrage of messages from the prominent vaccine skeptic, which the magazine described as 'miles and miles of texts,' contained numerous links to articles and websites peddling vaccine-autism conspiracies that Nye said he paid no real attention to. 'Just no self-awareness,' Nye said. 'And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection. I wrote him back and said, 'Okay, I'll read your book. I think you've confused causation with correlation. Your friend, Bill.'' The stream of messages did not end there, Nye said, even after he told Kennedy, 'Okay, no more texts.' 'He started again! So I cut him off,' Nye said. 'He does not have good judgment. He is not suited for this job.' The Department of Health and Human Services did not immediately respond to a request for comment from the Daily Beast. Kennedy has led a full-blown assault on vaccines as part of the Trump administration's campaign to restore public 'trust' in the lifesaving shots. That includes the shock move to fire all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP), an expert panel that evaluates vaccine safety and efficacy. All had been appointed under the Biden administration. In a Wall Street Journal op-ed, Kennedy said vaccines had become a 'divisive issue in American politics' and that public confidence in the health agencies that provide them is 'waning.' Nye said the increase in vaccine skepticism, which soared amid the COVID-19 pandemic, is having real life negative consequences on people's lives. That includes the reaction to a measles outbreak in Texas that primarily hit unvaccinated individuals in the Mennonite community. 'It was a religious sect with historically low vaccination rates. And the argument from the other side is: They have rights not to get vaccinated. No, you don't,' a frustrated Nye said. 'Unvaccinated people can, and usually do, spread a disease. And that's why we have these rules, for public health! It's not arbitrary. It's not about your rights. It's about my rights, people.' Nye didn't hold back on Kennedy's bizarre public stunts either—like chugging raw milk with health influencer Dr. Paul Saladino to promote the Trump administration's initially error-riddled Make America Healthy Again report on childhood illness. 'And then this thing where people want to drink raw milk. No, you don't,' Nye said. 'This is very well understood! Louis Pasteur! You guyyys! What is happening?' For more, listen to Bill Nye the Science Guy on The Last Laugh podcast.
Medscape
38 minutes ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
